source
- Biopharma workers increasingly postpone retirement, poll shows 52% plan to stay longerBiopharma professionals are rethinking retirement, with a BioSpace LinkedIn poll indicating that 52% expect to retire later than originally planned. Overall, 63% of respondents said they have chang…
- GSK licenses Chimagen trispecific T-cell engager for up to $750 million, targeting phase-1 multiple myeloma studyGSK has entered a licensing agreement with China’s Chimagen Biosciences that could be worth as much as $750 million. The deal will allow GSK to begin phase‑1 testing of a trispecific T‑cell engager…